Published in Cancer Epidemiol Biomarkers Prev on December 01, 2009
Electronic nicotine delivery systems: a research agenda. Tob Control (2011) 4.21
Abuse liability assessment of tobacco products including potential reduced exposure products. Cancer Epidemiol Biomarkers Prev (2009) 1.74
Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention. Chem Res Toxicol (2010) 1.58
Research opportunities related to establishing standards for tobacco products under the Family Smoking Prevention and Tobacco Control Act. Nicotine Tob Res (2011) 1.32
Oral tobacco products: preference and effects among smokers. Drug Alcohol Depend (2011) 1.18
Measures for assessing subjective effects of potential reduced-exposure products. Cancer Epidemiol Biomarkers Prev (2009) 1.05
Tobacco and nicotine product testing. Nicotine Tob Res (2011) 0.96
Does switching to reduced ignition propensity cigarettes alter smoking behavior or exposure to tobacco smoke constituents? Nicotine Tob Res (2010) 0.95
Tobacco harm reduction and the evolution of nicotine dependence. Am J Public Health (2011) 0.90
Postmarketing surveillance for "modified-risk" tobacco products. Nicotine Tob Res (2011) 0.88
Methods used in internal industry clinical trials to assess tobacco risk reduction. Cancer Epidemiol Biomarkers Prev (2009) 0.87
A single-blinded, single-centre, controlled study in healthy adult smokers to identify the effects of a reduced toxicant prototype cigarette on biomarkers of exposure and of biological effect versus commercial cigarettes. BMC Public Health (2013) 0.87
Evaluation of smoking-specific and generic quality of life measures in current and former smokers in Germany and the United States. Health Qual Life Outcomes (2015) 0.82
Preliminary Evaluation of a New German Translated Tobacco Quality of Life Impact Tool to Discriminate Between Healthy Current and Former Smokers and to Explore the Effect of Switching Smokers to a Reduced Toxicant Prototype Cigarette. Nicotine Tob Res (2015) 0.77
Providing a Science Base for the Evaluation of Tobacco Products. Tob Regul Sci (2015) 0.76
Expanding clinical laboratory tobacco product evaluation methods to loose-leaf tobacco vaporizers. Drug Alcohol Depend (2016) 0.75
Biomarkers of Tobacco Exposure: Summary of an FDA-Sponsored Public Workshop. Cancer Epidemiol Biomarkers Prev (2016) 0.75
Behavioral Economic Laboratory Research in Tobacco Regulatory Science. Tob Regul Sci (2016) 0.75
The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict (1991) 63.91
Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol (1988) 60.71
Half a century of research on the Stroop effect: an integrative review. Psychol Bull (1991) 11.38
Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N Engl J Med (1994) 6.75
Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988-1991. JAMA (1998) 6.73
Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet (2006) 5.85
Relation of nicotine yield of cigarettes to blood nicotine concentrations in smokers. Br Med J (1980) 4.76
Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet (2007) 3.84
Racial differences in serum cotinine levels among smokers in the Coronary Artery Risk Development in (Young) Adults study. Am J Public Health (1990) 3.82
The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US. Tob Control (2009) 3.10
Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther (1988) 3.05
Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. Cancer Res (1999) 2.99
Smoking in the absence of nicotine: behavioral, subjective and physiological effects over 11 days. Addiction (2007) 2.84
Clinical laboratory evaluation of potential reduced exposure products for smokers. Nicotine Tob Res (2006) 2.75
Comparison of effect on tobacco consumption and carbon monoxide absorption of changing to high and low nicotine cigarettes. Br Med J (1973) 2.65
Smoking topography, brand switching, and nicotine delivery: results from an in vivo study. Cancer Epidemiol Biomarkers Prev (2005) 2.59
Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. Cancer Epidemiol Biomarkers Prev (2007) 2.43
Cigarette tar yields in relation to mortality from lung cancer in the cancer prevention study II prospective cohort, 1982-8. BMJ (2004) 2.42
Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers. Am J Public Health (1994) 2.41
Nicotine intake and dose response when smoking reduced-nicotine content cigarettes. Clin Pharmacol Ther (2006) 2.35
Smokeless tobacco as a possible risk factor for myocardial infarction: a population-based study in middle-aged men. J Am Coll Cardiol (1999) 2.29
Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther (1999) 2.14
A prospectively measured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers. Cancer Epidemiol Biomarkers Prev (2009) 2.04
Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol (1993) 2.02
Tobacco and myocardial infarction: is snuff less dangerous than cigarettes? BMJ (1992) 2.00
Effects of reduced cigarette smoking on the uptake of a tobacco-specific lung carcinogen. J Natl Cancer Inst (2004) 1.99
Reduction of tar, nicotine and carbon monoxide intake in low tar smokers. J Epidemiol Community Health (1986) 1.98
New lower nicotine cigarettes can produce compensatory smoking and increased carbon monoxide exposure. Drug Alcohol Depend (2006) 1.85
Urinary levels of tobacco-specific nitrosamine metabolites in relation to lung cancer development in two prospective cohorts of cigarette smokers. Cancer Res (2009) 1.84
Evaluating acute effects of potential reduced-exposure products for smokers: clinical laboratory methodology. Nicotine Tob Res (2002) 1.84
Similar uptake of lung carcinogens by smokers of regular, light, and ultralight cigarettes. Cancer Epidemiol Biomarkers Prev (2005) 1.77
Evaluation of carcinogen exposure in people who used "reduced exposure" tobacco products. J Natl Cancer Inst (2004) 1.74
Similar exposure to a tobacco-specific carcinogen in smokeless tobacco users and cigarette smokers. Cancer Epidemiol Biomarkers Prev (2007) 1.66
Pharmacokinetics and pharmacodynamics of moist snuff in humans. Tob Control (1999) 1.58
Evaluation of biomarkers of exposure to selected cigarette smoke constituents in adult smokers switched to carbon-filtered cigarettes in short-term and long-term clinical studies. Nicotine Tob Res (2008) 1.53
Toward a comprehensive long term nicotine policy. Tob Control (2005) 1.52
Randomised trial investigating effect of a novel nicotine delivery device (Eclipse) and a nicotine oral inhaler on smoking behaviour, nicotine and carbon monoxide exposure, and motivation to quit. Tob Control (2000) 1.51
Sex differences in the subjective and reinforcing effects of cigarette nicotine dose. Psychopharmacology (Berl) (2002) 1.51
Acute effects of Advance: a potential reduced exposure product for smokers. Tob Control (2002) 1.50
Cigarette smoking, oral moist snuff use and glucose intolerance. J Intern Med (2000) 1.45
Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev (2002) 1.41
Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res (2006) 1.37
Methods to assess potential reduced exposure products. Nicotine Tob Res (2005) 1.36
Nicotine delivery, cardiovascular profile, and subjective effects of an oral tobacco product for smokers. Nicotine Tob Res (2008) 1.36
Withdrawal-suppressing effects of a novel smoking system: comparison with own brand, not own brand, and de-nicotinized cigarettes. Nicotine Tob Res (2001) 1.35
Pharmacodynamic effects of new de-nicotinized cigarettes. Nicotine Tob Res (1999) 1.35
Substitutes for tobacco smoking: a behavioral economic analysis of nicotine gum, denicotinized cigarettes, and nicotine-containing cigarettes. Drug Alcohol Depend (2004) 1.32
Comparing the reinforcing efficacy of nicotine containing and de-nicotinized cigarettes: a behavioral economic analysis. Psychopharmacology (Berl) (1999) 1.31
Carcinogen exposure during short-term switching from regular to "light" cigarettes. Cancer Epidemiol Biomarkers Prev (2005) 1.31
Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge. Tob Control (2007) 1.30
Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend (2003) 1.30
Differences in the urinary metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in black and white smokers. Cancer Epidemiol Biomarkers Prev (1997) 1.27
Smoking without nicotine delivery decreases withdrawal in 12-hour abstinent smokers. Pharmacol Biochem Behav (1995) 1.24
Oral mucosal changes and nicotine disposition in users of Swedish smokeless tobacco products: a comparative study. J Oral Pathol Med (1994) 1.24
Cigarette smoking as a risk for cardiovascular disease V: Biochemical parameters with increased and decreased nicotine content cigarettes. Addict Behav (1984) 1.24
Pilot study on lower nitrosamine smokeless tobacco products compared with medicinal nicotine. Nicotine Tob Res (2007) 1.23
Smoking topography in response to denicotinized and high-yield nicotine cigarettes in adolescent smokers. J Adolesc Health (2006) 1.22
Nicotine-containing versus de-nicotinized cigarettes: effects on craving and withdrawal. Pharmacol Biochem Behav (1997) 1.22
Effects of cigarette nicotine content and smoking pace on subsequent craving and smoking. Psychopharmacology (Berl) (2002) 1.19
Short-term clinical exposure evaluation of a second-generation electrically heated cigarette smoking system. J Clin Pharmacol (2007) 1.19
Potential reduced exposure products (PREPs) for smokeless tobacco users: clinical evaluation methodology. Nicotine Tob Res (2008) 1.18
Steady-state nicotine plasma levels following use of four different types of Swedish snus compared with 2-mg Nicorette chewing gum: a crossover study. Nicotine Tob Res (2005) 1.18
Carbon monoxide yield of cigarettes and its relation to cardiorespiratory disease. Br Med J (Clin Res Ed) (1983) 1.16
Developing the science base for reducing tobacco harm. Nicotine Tob Res (2007) 1.15
The effect of a novel smoking system--Accord--on ongoing smoking and toxin exposure. Nicotine Tob Res (2004) 1.13
Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin. The Northern Sweden MONICA Study. Atherosclerosis (1995) 1.12
Cotinine concentration in smokers from different countries: relationship with amount smoked and cigarette type. Cancer Epidemiol Biomarkers Prev (2006) 1.10
A double-blind randomized controlled trial of the effect of a low- versus a middle-tar cigarette on respiratory symptoms--a feasibility study. IARC Sci Publ (1986) 1.08
Tobacco specific nitrosamines and potential reduced exposure products for smokers: a preliminary evaluation of Advance. Tob Control (2003) 1.04
Urinary tobacco-specific nitrosamines and 4-aminobiphenyl hemoglobin adducts measured in smokers of either regular or light cigarettes. Nicotine Tob Res (2005) 1.03
Effects of low nicotine content cigarettes on smoke intake. Nicotine Tob Res (2004) 1.03
Preliminary evaluation of a novel smoking system: effects on subjective and physiological measures and on smoking behavior. Nicotine Tob Res (2000) 1.02
Long-term effects of the Eclipse cigarette substitute and the nicotine inhaler in smokers not interested in quitting. Nicotine Tob Res (2002) 1.02
Smokeless tobacco and coronary heart disease: a 12-year follow-up study. Eur J Cardiovasc Prev Rehabil (2005) 1.02
Carotid and femoral atherosclerosis, cardiovascular risk factors and C-reactive protein in relation to smokeless tobacco use or smoking in 58-year-old men. J Intern Med (2001) 1.00
The tar reduction study: randomised trial of the effect of cigarette tar yield reduction on compensatory smoking. Thorax (1995) 1.00
Effect of delivered dosage of cigarette smoke toxins on the levels of urinary biomarkers of exposure. Cancer Epidemiol Biomarkers Prev (2007) 1.00
Nicotine discrimination in men and women. Pharmacol Biochem Behav (1999) 1.00
Sensitivity of nicotine-containing and de-nicotinized cigarette consumption to alternative non-drug reinforcement: a behavioral economic analysis. Behav Pharmacol (2001) 0.98
A 12-month, randomized, controlled study to evaluate exposure and cardiovascular risk factors in adult smokers switching from conventional cigarettes to a second-generation electrically heated cigarette smoking system. J Clin Pharmacol (2008) 0.96
Symptoms of tobacco withdrawal from total cigarette cessation versus partial cigarette reduction. Psychopharmacology (Berl) (1988) 0.95
Nicotine replacement therapy. Prim Care (1999) 0.94
Use of Swedish moist snuff, smoking and alcohol consumption in the aetiology of oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden. Acta Otolaryngol (2005) 0.94
Do smokers of lower tar cigarettes consume lower amounts of smoke components? Results from the Scottish Heart Health Study. Br J Addict (1992) 0.93
Placebo cigarettes in a spaced smoking paradigm. Pharmacol Biochem Behav (2005) 0.92
Lung cancer and type of cigarette smoked. Inhal Toxicol (2001) 0.92
Short-term exposure evaluation of adult smokers switching from conventional to first-generation electrically heated cigarettes during controlled smoking. J Clin Pharmacol (2005) 0.92
Nicotine availability from Eclipse tobacco-heating cigarette. Psychopharmacology (Berl) (1998) 0.92
Metabolites of a tobacco-specific nitrosamine, 4-(methylnitrosamino)- 1-(3-pyridyl)-1-butanone (NNK), in the urine of smokeless tobacco users: relationship between urinary biomarkers and oral leukoplakia. Cancer Epidemiol Biomarkers Prev (1996) 0.92
Subjective and discriminative stimulus effects of two de-nicotinized cigarettes with different tar yields. Nicotine Tob Res (2001) 0.92
Cigarette smoking as a risk for cardiovascular disease III: Biochemical effects with higher nicotine yield cigarettes. Addict Behav (1983) 0.91
Human urine mutagenicity study comparing cigarettes which burn or primarily heat tobacco. Mutat Res (1996) 0.91
Comparison of the effects of nicotine on a fixed rate and a subject-paced version of the rapid information processing task. Psychopharmacology (Berl) (1995) 0.91
Evaluation of a low to middle tar/medium nicotine cigarette designed to maintain nicotine delivery to the smoker. Psychopharmacology (Berl) (1988) 0.89
A randomized, controlled exposure study in adult smokers of full flavor Marlboro cigarettes switching to Marlboro Lights or Marlboro Ultra Lights cigarettes. Regul Toxicol Pharmacol (2008) 0.87
A comparative study of the amount of smoke absorbed from low yield ('less hazardous') cigarettes. Part 1: Non-invasive measures. Br J Addict (1982) 0.87
Smoking behaviour and toxin exposure during six weeks use of a potential reduced exposure product: Omni. Tob Control (2004) 0.86
Long-term effects of switching to cigarettes with lower tar and nicotine yields. Psychopharmacology (Berl) (1989) 0.86
Conference on abuse liability assessment of CNS drugs. Drug Alcohol Depend (2003) 0.86
Genetic variation and cancer: improving the environment for publication of association studies. Cancer Epidemiol Biomarkers Prev (2004) 6.24
Novel nicotine delivery systems and public health: the rise of the "e-cigarette". Am J Public Health (2010) 4.21
Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. Addiction (2010) 3.26
Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: failure to replicate and finding that never-smokers may be different. Nicotine Tob Res (2002) 3.19
Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes. Diabetes Educ (2003) 3.05
Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol (2009) 2.52
Reach, efficacy, and cost-effectiveness of free nicotine medication giveaway programs. J Public Health Manag Pract (2005) 2.51
Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther (2006) 2.49
Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst (2006) 2.42
Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. J Natl Cancer Inst (2008) 2.17
Cigarette smoking, N-acetyltransferase 2 genotypes, and breast cancer risk: pooled analysis and meta-analysis. Cancer Epidemiol Biomarkers Prev (2008) 1.97
Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. J Nutr (2004) 1.90
Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. Chem Res Toxicol (2009) 1.89
The role of CYP2A6 in the emergence of nicotine dependence in adolescents. Pediatrics (2006) 1.83
Reconciling human smoking behavior and machine smoking patterns: implications for understanding smoking behavior and the impact on laboratory studies. Cancer Epidemiol Biomarkers Prev (2009) 1.82
The etiology of alcohol-induced breast cancer. Alcohol (2005) 1.73
Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology (2003) 1.70
Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol (2008) 1.70
Lack of diagnostic and prognostic utility of circulating plasma myeloperoxidase concentrations in patients presenting with dyspnea. Clin Chem (2008) 1.57
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol (2004) 1.51
Interacting effects of genetic predisposition and depression on adolescent smoking progression. Am J Psychiatry (2004) 1.50
A prospective cohort study of bladder cancer risk in relation to active cigarette smoking and household exposure to secondhand cigarette smoke. Am J Epidemiol (2007) 1.44
Prevalence and correlates of roll-your-own smoking in Thailand and Malaysia: Findings of the ITC-South East Asia Survey. Nicotine Tob Res (2008) 1.40
Presence of the carcinogen N'-nitrosonornicotine in the urine of some users of oral nicotine replacement therapy products. Cancer Res (2009) 1.38
Relation between food reinforcement and dopamine genotypes and its effect on food intake in smokers. Am J Clin Nutr (2004) 1.34
Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol (2003) 1.32
Bleomycin-induced chromosome breaks as a risk marker for lung cancer: a case-control study with population and hospital controls. Carcinogenesis (2003) 1.31
Evaluation of in vitro assays for assessing the toxicity of cigarette smoke and smokeless tobacco. Cancer Epidemiol Biomarkers Prev (2009) 1.30
Active and passive cigarette smoking and the risk of cervical neoplasia. Obstet Gynecol (2005) 1.29
Women's experiences receiving abnormal prenatal chromosomal microarray testing results. Genet Med (2012) 1.28
Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res (2007) 1.26
Cruciferous vegetables, genetic polymorphisms in glutathione S-transferases M1 and T1, and prostate cancer risk. Nutr Cancer (2004) 1.24
The cigarette controversy. Cancer Epidemiol Biomarkers Prev (2007) 1.24
Surveillance methods for identifying, characterizing, and monitoring tobacco products: potential reduced exposure products as an example. Cancer Epidemiol Biomarkers Prev (2009) 1.24
Trends in beliefs about the harmfulness and use of stop-smoking medications and smokeless tobacco products among cigarettes smokers: Findings from the ITC four-country survey. Harm Reduct J (2011) 1.24
Ionizing radiation and tobacco use increases the risk of a subsequent lung carcinoma in women with breast cancer: case-only design. J Clin Oncol (2005) 1.22
Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res (2007) 1.21
What do cigarette pack colors communicate to smokers in the U.S.? Am J Prev Med (2011) 1.21
Smoking and risk of fatal prostate cancer in a prospective U.S. study. Urology (2007) 1.18
Mutagen sensitivity has high heritability: evidence from a twin study. Cancer Res (2006) 1.16
Associations between cigarette smoking and mitochondrial DNA abnormalities in buccal cells. Carcinogenesis (2008) 1.13
Assessing consumer responses to potential reduced-exposure tobacco products: a review of tobacco industry and independent research methods. Cancer Epidemiol Biomarkers Prev (2009) 1.13
Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics (2002) 1.13
Effect of team sport participation on genetic predisposition to adolescent smoking progression. Arch Gen Psychiatry (2006) 1.12
Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet Genomics (2005) 1.11
MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev (2006) 1.10
DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat (2008) 1.10
Can the blind see? Participant guess about treatment arm assignment may influence outcome in a clinical trial of bupropion for smoking cessation. J Subst Abuse Treat (2007) 1.08
Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. Cancer Causes Control (2011) 1.06
Infection with Brugia microfilariae induces apoptosis of CD4(+) T lymphocytes: a mechanism of immune unresponsiveness in filariasis. Eur J Immunol (2002) 1.05
Measures for assessing subjective effects of potential reduced-exposure products. Cancer Epidemiol Biomarkers Prev (2009) 1.05
Less efficient g2-m checkpoint is associated with an increased risk of lung cancer in African Americans. Cancer Res (2005) 1.05
Mutagen sensitivity and genetic variants in nucleotide excision repair pathway: genotype-phenotype correlation. Cancer Epidemiol Biomarkers Prev (2007) 1.05
Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene. J Natl Cancer Inst (2007) 1.05
Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. Cancer Epidemiol Biomarkers Prev (2007) 1.05
Skilled use of DNA polymorphisms as a tool for polygenic cancers. Carcinogenesis (2002) 1.04
Childhood exposure to secondhand smoke and functional mannose binding lectin polymorphisms are associated with increased lung cancer risk. Cancer Epidemiol Biomarkers Prev (2009) 1.04
Chromosome 9 arm-specific telomere length and breast cancer risk. Carcinogenesis (2009) 1.03
Consumption of single cigarettes and quitting behavior: a longitudinal analysis of Mexican smokers. BMC Public Health (2011) 1.03
Activation of CD4⁺ Foxp3⁺ regulatory T cells proceeds normally in the absence of B cells during EAE. Eur J Immunol (2012) 1.02
p53 Mutation analysis in breast tumors by a DNA microarray method. Cancer Epidemiol Biomarkers Prev (2006) 1.02
A meta-analysis of the effectiveness of albendazole compared with metronidazole as treatments for infections with Giardia duodenalis. PLoS Negl Trop Dis (2010) 1.01
Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control (2010) 1.01
Food mutagens. J Nutr (2003) 1.00
Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res (2013) 1.00
Tobacco and cancer: an American Association for Cancer Research policy statement. Cancer Res (2010) 0.99
CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev (2007) 0.98
Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev (2006) 0.98
Changes in food reward following smoking cessation: a pharmacogenetic investigation. Psychopharmacology (Berl) (2004) 0.97
Accurate genotyping from paraffin-embedded normal tissue adjacent to breast cancer. Carcinogenesis (2005) 0.97
Pancreaticoduodenectomy can be performed safely in patients aged 80 years and older. J Gastrointest Surg (2010) 0.97
Single-nucleotide polymorphisms in DNA repair genes and association with breast cancer risk in the web study. Carcinogenesis (2011) 0.97
One hundred thirty resections for pancreatic neuroendocrine tumor: evaluating the impact of minimally invasive and parenchyma-sparing techniques. J Gastrointest Surg (2010) 0.96
Available carbohydrates, glycemic load, and pancreatic cancer: is there a link? Am J Epidemiol (2010) 0.95
Vitamin D receptor gene polymorphisms are associated with adiposity phenotypes. Am J Clin Nutr (2010) 0.95
Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev (2008) 0.95
Green and black tea intake in relation to prostate cancer risk among Singapore Chinese. Cancer Causes Control (2012) 0.94
Knowledge, attitudes, and behaviors toward skin cancer in Maryland youths. J Adolesc Health (2002) 0.94
Polymorphisms in XPD and TP53 and mutation in human lung cancer. Carcinogenesis (2004) 0.94
Use of nonsteroidal anti-inflammatory drugs and survival following breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev (2011) 0.94
Metabolic polymorphisms, smoking, and oral cancer in Puerto Rico. Oncol Res (2004) 0.94
Active cigarette smoking, household passive smoke exposure, and the risk of developing pancreatic cancer. Prev Med (2006) 0.93
Adipokines in plasma and breast tissues: associations with breast cancer risk factors. Cancer Epidemiol Biomarkers Prev (2012) 0.93
Recruitment for a clinical trial of drug treatment for benign prostatic hyperplasia. Urology (2002) 0.93
Intake of fruits and vegetables and risk of pancreatic cancer in a pooled analysis of 14 cohort studies. Am J Epidemiol (2012) 0.93
Fruits and vegetables and ovarian cancer risk in a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev (2005) 0.92
Cigarette filter-based assays as proxies for toxicant exposure and smoking behavior--a literature review. Cancer Epidemiol Biomarkers Prev (2009) 0.92
Mortality among capacitor workers exposed to polychlorinated biphenyls (PCBs), a long-term update. Int Arch Occup Environ Health (2014) 0.92
Alcohol consumption and genetic variation in methylenetetrahydrofolate reductase and 5-methyltetrahydrofolate-homocysteine methyltransferase in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev (2009) 0.91
Nicotine withdrawal and craving in adolescents: effects of sex and hormonal contraceptive use. Addict Behav (2009) 0.91
Exposures associated with serum organochlorine levels among postmenopausal women from western New York State. Am J Ind Med (2002) 0.91
DNA promoter methylation in breast tumors: no association with genetic polymorphisms in MTHFR and MTR. Cancer Epidemiol Biomarkers Prev (2009) 0.90
Interleukin-4 influences the production of microfilariae in a mouse model of Brugia infection. Parasite Immunol (2002) 0.90
Elevated lung cancer risk is associated with deficiencies in cell cycle checkpoints: genotype and phenotype analyses from a case-control study. Int J Cancer (2010) 0.90
New NCCN Guidelines: Smoking Cessation for Patients With Cancer. J Natl Compr Canc Netw (2015) 0.90
Alcohol consumption in relation to aberrant DNA methylation in breast tumors. Alcohol (2010) 0.90
Bayesian sensitivity analysis methods to evaluate bias due to misclassification and missing data using informative priors and external validation data. Cancer Epidemiol (2013) 0.89
Correcting over 50 years of tobacco industry misinformation. Am J Prev Med (2011) 0.89